Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BICYCL

Market Cap 281M 242M 223M 210M 394M 26.49B 397M 2.64B 1.03B 13B 1.05B 1.03B 44.97B P/E 2026 *
-1.73x
P/E 2027 * -1.91x
Enterprise Value -231M -200M -183M -173M -325M -21.83B -327M -2.17B -847M -10.72B -868M -850M -37.07B EV / Sales 2026 *
-12.7x
EV / Sales 2027 * -8.75x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 75 01/01/2009
Director/Board Member 57 01/09/2015
Director/Board Member 69 18/07/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 281M
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.04%+7.05%-12.15%-16.12% 22.63B
+3.07%+7.15%-1.82%+387.14% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
+0.65%-0.27%+26.80%+176.87% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.27%+6.06%+78.78%+103.63% 11.56B
Average +0.93%+0.18%+25.94%+90.78% 23.3B
Weighted average by Cap. +1.52%+0.18%+32.14%+90.45%

Financials

2026 *2027 *
Net sales 18.24M 15.73M 14.46M 13.61M 25.58M 1.72B 25.8M 171M 66.73M 845M 68.44M 66.98M 2.92B 14.11M 12.18M 11.19M 10.54M 19.8M 1.33B 19.96M 133M 51.64M 654M 52.97M 51.84M 2.26B
Net income -154M -133M -122M -115M -216M -14.5B -217M -1.44B -562M -7.12B -577M -564M -24.62B -162M -140M -129M -121M -228M -15.32B -230M -1.53B -594M -7.52B -609M -596M -26.01B
Net Debt -512M -442M -406M -382M -718M -48.32B -724M -4.81B -1.87B -23.71B -1.92B -1.88B -82.04B -404M -349M -321M -302M -567M -38.14B -572M -3.8B -1.48B -18.72B -1.52B -1.48B -64.76B
Logo BICYCL
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!